

Is this really the end of internal optimisation?

- Most firms conducted large optimisation activities in the run-up to Solvency II.
- There are still areas insurers can improve (e.g. asset restructuring), but these are likely to have a smaller impact than the initial surge.
- Insurers always need to be prepared for regulatory change, which may result in optimisation – but this is likely to be reactive.

Large transformative optimisation techniques are more likely to be externally focussed in the future.

Upcoming regulatory changes (may lead to some level of optimisation):





PRA's CP on the MA allowed for liabilities backed by ERMs.


PRA's guidance of modelling DVA for IM firms.

 $\ensuremath{\mathsf{TMTP}}$ and Liquidity guidance from the PRA likely to be published in the near future.



20 November 2018

External optimisation - longevity risk transfer





Source: http://www.artemis.bm/libran/longevity swaps risk transfers.htm Includes longevity risk transfers from insurance companies to reinsurers. Excludes pension buy-ins/buy-outs and pass-through deals to reinsurers.

- Longevity risk transfer from the UK is likely to
- Increase in asset based deals along with longevity risk transfer in recent years
- Driven by Solvency II capital requirements for annuity business.
- Insurers' back-book is likely to be sufficiently optimised.
- Ongoing risk transfer is expected as pension buyin and buy-out activity continues.




20 November 2018 6





Case study 1: Reinsurance/M&A of EEA life risks to Bermuda




Benefits of Bermuda Hold Co structure

- · Reduced political risk, e.g. from UK's departure from the EU.
- UK/EEA holding company allows ease of future M&A activity in the EEA.
- Bermuda reinsurer allows reinsurance to Solvency II equivalent regime which may be more capital efficient.
- Bermuda one of the largest reinsurance jurisdictions in the world with a respected regulator.
- Can include EEA reinsurer in structure, to reinsure risks from jurisdictions that penalise reinsurance to Bermuda (e.g. Belgium). This may increase diversification benefits – i.e. "mixing risks".



Page 9

Case study 2: EEA based group acquiring non-EEA business



Considerations around acquiring business through an insurer or a branch in an equivalent regime

- Subsidiary may allow local capital requirements at Group level under Solvency II D&A rules
- · Branch may allow diversification with other business in the host entity
- Cash efficiency
- · Capital efficiency at entity level
- Tax efficiency
- Intra-group reinsurance
- · Market competitiveness



Page 10

Conclusion



Optimisation is still high on the agenda Internal:

- Still an area of activity, but most of the immediate work completed.
- · More likely to be bespoke, strategic and reactive.



External:

- · Firms continue to look strategically at their businesses.
- Increasing appetite to take big decisions, which is unlikely to reduce in the future.



New entrants are increasingly set up with capital efficient structures embedded from outset. Consolidators are reinsuring and buying European insurance risk.



How does Brexit impact the optimisation landscape?



20 November 2018

Questions Comments

The views expressed in this [publication/presentation] are those of invited contributors and not necessarily those of the IFoA. The IFoA do not endorse any of the views stated, nor any claims or representations made in this [publication/presentation] and accept no responsibility or liability to any person for loss or damage suffered as a consequence of their placing reliance upon any view, claim or representation made in this [publication/presentation].

The information and expressions of opinion contained in this publication are not intended to be a comprehensive study, nor to provide actuarial advice or advice of any nature and should not be treated as a substitute for specific advice concerning individual situations. On no account may any part of this [publication/presentation] be reproduced without the written permission of the IFoA [or authors, in the case of non-IFoA research].



20 November 2018